Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
토요일, 8월 29

Roivant Sciences Ltd

ROIVNASDAQ
Trade with Public
Trade with Public
$34.71
-2.87-7.64%
가까이에: Aug 28, 5:00 PM EST
$35.11
0.401.15%
시간외: 5:42 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Roivant Sciences Financials

Roivant Sciences (ROIV) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Roivant Sciences Q1 Adj. EPS $(0.34) Misses $(0.32) Estimate, Sales $1.442M Miss $2.057M Estimate

Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.32) by 6.25 percent. This is a 36 percent decrease over losses of $(0.25) per share from
Benzinga Newsdesk

S&P 500 Rebounds Ahead Of Nvidia's Print, Oil Sinks 5% On Iran Truce Hopes: Stock Market Today

U.S. stocks halt a three-day slide as oil tumbles 5% on revived Iran truce hopes, easing inflation fears ahead of Nvidia's results after the close.
Piero Cingari

Earnings Scheduled For May 20, 2026

Benzinga Insights

PRO
Roivant Sciences Q4 Adj. EPS $(0.27) Beats $(0.34) Estimate

Benzinga Newsdesk

PRO
Roivant Sciences Q4 Sales $2.520M Miss $3.820M Estimate

Benzinga Newsdesk

Roivant Stock Soars On Experimental Skin Drug Delivering 100% Response - Why It Matters

Roivant shares surged after its skin disease drug brepocitinib showed strong Phase 2 results, with high response rates, early benefits, and no serious safety issues.
Vandana Singh

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved